Evidence explorer
Every claim we hold, and how far we can stand behind it.
142 claims across 39 products. 30% are confirmed against the source text by the evidence gate; 39% come from a class with no vendor interest. Everything below is browsable, filterable, and available as JSON.
What this corpus is made of
| Evidence class | Claims | Confirmed | What it can support |
|---|---|---|---|
| Peer-reviewed study | 19 | 5 | Independent review before publication. The only class that survives a sceptical committee unaided. |
| Regulatory filing | 4 | 0 | A statement made to a regulator, where being wrong has consequences. |
| Independent report | 32 | 9 | Analysis by someone with no stake in the sale. |
| Customer case | 4 | 3 | A real deployment, but selected and framed by someone with an interest. |
| Press release | 63 | 23 | The vendor's own announcement. Useful for dates and facts, not for outcomes. |
| Vendor page | 20 | 2 | Marketing copy. Establishes what is claimed, never that it is true. |
Showing 1 of 1 matching claims (142 in the full corpus) · 0% of this selection is confirmed · clear filters
AKASA blog (Aug 19, 2025) on Cleveland Clinic's mid-cycle GenAI deployment: in the first 60 days of production with the AKASA mid-cycle Optimization Suite, Cleveland Clinic experienced roughly a 50% acceptance rate for AI-flagged recommendations, higher ICD-10 capture and case mix index, and improved severity of illness, risk of mortality, and HCC capture.
Provenance
- Claim ID
- clm_b426c758a49f6c36d28c
- Version
- 1
- Workflow
- Revenue Cycle / Coding / Prior Auth
- Dimension
- economic value
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://akasa.com/blog/cleveland-clinic-genai-leap-midcycle